Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections.

A considerable number of patients with malignancies who are treated with high-dose therapy and hematopoietic stem cell transplantation subsequently relapse. Analyses of peripheral blood stem cell (PBSC) harvests obtained from 49 cancer patients showed that the PBSC harvest contained precursors for antitumor effector cells. Ex vivo manipulation of these harvests to maximize the antitumor effector cell activity may provide a new therapeutic approach to decrease or eliminate any minimal residual disease that remains after high-dose therapy. Characterization of PBSC from consecutive collections determined the collections best suited for ex vivo augmentation of antitumor cytotoxic effector cells. We report the results of a functional and phenotypical characterization of PBSC obtained from six consecutive collections from 18 cancer patients receiving granulocyte-macrophage colony-stimulating factor (GM-CSF) for hematopoietic stem/progenitor cell mobilization. The PBSC were evaluated for their cytotoxicity using the 51Cr-release assay. The frequency and subsets of lymphocytes were determined using flow cytometry with appropriate specific marker antibodies and differential cell counts. The content of hematopoietic progenitor cells in each collection was determined using a colony-forming unit granulocyte-macrophage (CFU-GM) culture assay. The frequency of cytotoxic effector cells including lymphokine-activated killer (LAK) cell precursors and lymphocytes was significantly greater (P < .05) in the early collections, whereas the later collections contained significantly (P < .05) more CFU-GM progenitor cells and fewer cytotoxic effector cells. Thus, our results show that PBSC obtained from advanced cancer patients do contain considerable levels of precursor cells for the generation of LAK cell populations. These results suggest that cells from the earlier collections are best suited for ex vivo manipulation to augment the antitumor effects.

[1]  H. Deeg,et al.  Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Armitage,et al.  High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Linehan,et al.  Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. , 1993, The Journal of urology.

[4]  Y. Lévy,et al.  Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. , 1989, Blood.

[5]  J. Schiller,et al.  Activation of multiple effector mechanisms to enhance tumor immunotherapy. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[6]  D. Longo,et al.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. , 1993, The Journal of clinical investigation.

[7]  J. Jackson,et al.  Cell surface properties associated with malignancy of metastatic large cell lymphoma cells. , 1987, Cancer research.

[8]  J. Armitage,et al.  High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft , 1994 .

[9]  J. Armitage,et al.  High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. , 1991, Experimental hematology.

[10]  J. Armitage,et al.  High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. , 1991, Blood.

[11]  M. Boogaerts,et al.  Bone marrow transplantation in a patient with secondary leukemia , 1982 .

[12]  J. Armitage,et al.  High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. , 1994, Blood.

[13]  I. Schmidt-Wolf,et al.  Lymphokine-activated killer cell activity after cryopreservation. , 1989, Journal of immunological methods.

[14]  A. Nagler,et al.  Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. , 1992, Cancer investigation.

[15]  A. Carella,et al.  Autologous unpurged bone marrow transplantation for acute non-lymphoblastic leukaemia in first complete remission. , 1988, Bone marrow transplantation.

[16]  S. Slavin,et al.  Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated , 1992, Cancer investigation.

[17]  L. To,et al.  Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. , 1988, Transplantation proceedings.

[18]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[19]  E. Barker,et al.  Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach. , 1990, Bone marrow transplantation.

[20]  S. Joshi,et al.  Differential susceptibility of metastatic lymphoma cells to natural immunity. , 1990, Oncology.

[21]  G. H. Weiss,et al.  Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. , 1993, Urology.

[22]  J. Thompson,et al.  Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. , 1994, Bone marrow transplantation.

[23]  R. Holle,et al.  Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.